Bruker invests in Acuity's in situ spatial genomics platform

By The Science Advisory Board staff writers

Acuity Spatial Genomics has announced the completion of a majority investment by Bruker.

Acuity, a Harvard Medical School spinoff, is focused on spatial 3D genomic and multiomic analysis for discovery. The genomic measurements captured through the spatial biology technology (and in the context of the transcriptome and proteome) will provide a critical understanding of the complete multiomic picture, the firm said.

The company's single-cell and accelerated super-resolution technology was designed to allow researchers to gain insights into the 3D relationships between chromosomes, gene identities, and their spatial position in the nucleus. The technology also will further insight into physical gene positioning on chromosomes, chromosome 3D conformations, chromosome and gene copy number variations, chromosomal compartments, topologically associating domains (TADs) and loops, and spatially resolved enhancer-promoter interactions.

Acuity plans to continue to commercialize the OligoFisseq and OligoFisseq high-definition technologies at the core of the in situ genome visualization platform. The platform provides insights into transcription regulatory programs that drive cell type, state, function, and pathogenesis and will help to advance knowledge in various fields of biology research.

Mark Munch, PhD, president of the Brukers Nano Group, will serve as the Acuity CEO.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?